Advertisement
Organisation › Details
Syncona Partners LLP
Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Syncona’s vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders. Its current investment portfolio consists of seven high quality companies in life science and a leading range of fund investments. Syncona seeks to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. It is an established leader in gene therapy, cell therapy and advanced diagnostics, and focuses on delivering dramatic efficacy for patients in areas of high unmet need. Syncona’s fund investments represent a productively deployed evergreen funding base which enables the business to take a long-term approach to investing in life sciences as its targets the best new opportunities and supports its existing portfolio companies to grow and succeed. Syncona is aligned with two of the premium charitable funders in UK science, the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both of which are significant shareholders in the business. Syncona makes a donation of 0.3% of Net Asset Value to a range of charities each year. *
Start | 2012-08-28 established pred | |
End | 2018-06-19 reorganised before | |
Group | Syncona (Group) | |
Today | Syncona Ltd. (LON: SYNC) | |
Predecessor | Wellcome Trust, Sigma project | |
Successor | Syncona Ltd. (LON: SYNC) | |
Industry | venture capital | |
Industry 2 | LIFE SCIENCES | |
Person | Murphy, Martin (Syncona CEO before Wellcome Trust Sigma project + MVM Life Science Partners + 3i + McKinsey) | |
Person 2 | Keen, Nigel (Axis-Shield 200606 Chairman) | |
Region | London, Greater London | |
Country | United Kingdom (GB) | |
Street | 215 Euston Road | |
City | NW1 2BE London | |
Tel | +44-20-7611-2031 | |
Address record changed: 2022-03-19 | ||
Basic data | Employees | n. a. |
Currency | GBP | |
Annual sales | 200,000,000 (assets, managed 2014-12-16) | |
* Document for »About Section«: Freeline Therapeutics Ltd.. (6/19/18). "Press Release: Freeline Secures Over £88 Million of Funding". London. | ||
Record changed: 2021-02-21 |
Advertisement
More documents for Syncona (Group)
- [1] Freeline Therapeutics Holdings plc. (11/22/23). "Press Release: Syncona to Acquire Freeline Therapeutics". London....
- [2] Beacon Therapeutics Holdings Ltd.. (6/12/23). "Press Release: Beacon Therapeutics Launches with £96 Million ($120 Million) to Develop a New Generation of Gene Therapies for Retinal Diseases Resulting in Blindness". London & Oxford....
- [3] Syncona Ltd.. (4/5/23). "Press Release: Syncona Appoints Roel Bulthuis as Managing Partner"....
- [4] SwanBio Therapeutics, Inc.. (5/18/22). "Press Release: SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies for Neurological Conditions". Philadeliphia, PA....
- [5] Clade Therapeutics Inc.. (11/3/21). "Press Release: Clade Therapeutics Raises $87 Million Series A Financing to Realize the Potential of Cell Therapy". Cambridge, MA....
- [6] Purespring Therapeutics Ltd.. (7/30/21). "Press Release: Syncona Founds Purespring with a £45m Series A Financing"....
- [7] Quell Therapeutics Ltd.. (2/11/21). "Press Release: Quell Therapeutics Expands Series A Financing to $84 Million". London....
- [8] Syncona Ltd.. (12/2/20). "Press Release: Resolution Therapeutics Announces a £26.6m Series A Financing from Syncona Ltd"....
- [9] Achilles Therapeutics Ltd.. (12/1/20). "Press Release: Achilles Therapeutics Appoints Robert Coutts as Chief Financial Officer". Stevenage....
- [10] Freeline Therapeutics Ltd.. (6/30/20). "Press Release: Freeline Closes $120 Million Series C Financing Round". London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top